Korean journal of dermatology (대한피부과학회지)

Korean Dermatological Association (대한피부과학회)
권호 표지

Report from ADRG: The Treatment Guideline of Korean Atopic Dermatitis

아토피피부염학회 보고서: 한국 아토피피부염의 치료지침

Lee, Ji-Hyeon;Kim, Gyu-Han;Kim, Myeong-Nam;Kim, Jin-U;No, Yeong-Seok;Park, Yeong-Rip;Park, Cheon-Uk;Lee, Gwang-Hun;Lee, Ae-Yeong;Jo, Sang-Hyeon;Choe, Ji-Ho
이지현;김규한;김명남;김진우;노영석;박영립;박천욱;이광훈;이애영;조상현;최지호

  • Published : 20060000
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Ring J, Brockow K, Abeck D. The therapeutic concept of 'patient management' in atopic eczema. Allergy 1995;51:206-215
  2. Abeck D, Strom K. Optimal management of atopic dermatitis. Am Clin Dermatol 2000;1:41-46 https://doi.org/10.2165/00128071-200001010-00004
  3. Choi HJ, Kim KH, Kim MN, Kim JW, Ro YS, Park CW, et al. Report of ARDG: a study on triggering factors in Korean adult atopic dermatitis through questionnaire. Korean J Dermatol 2004;42:1152-1160
  4. Ellis C, Luger T. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003;148(Suppl 63):S3-S10
  5. Leung DYM, Eichenfield LF, Boguniewicz M. Atopicdermatitis (atopic eczema), In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith KA, Katz SI, editors. Dermatology in general medicine. 6th ed. New York: McGraw- Hill, 2003:1180-1194
  6. William DJ, Timothy GB, Dirk ME. Andrew's disease of the skin. 10th ed. Philadelphia: Saunders, 2006:69-79
  7. Hanifin JM. Atopic dermatitis, In: Moschella SL, Hurley HJ, editors. Dermatology. 3rd ed. Philadelphia: W.B. Saunders, 1992:441-464
  8. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin disease: in vitro pharmacology. Br J Dermatol 1999;141:264-273 https://doi.org/10.1046/j.1365-2133.1999.02974.x
  9. Zuberbier T, Chong S. The ascomycin macrolactam pime pimeclolimus(Elidel□, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001;108:275-280 https://doi.org/10.1067/mai.2001.116865
  10. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel□, SDZ ASM 981) preclinical pharmacologic profile and skin selectivity. Sem Cutan Med Surg 2001;20:233-241
  11. Harper J, Green A, Scott G, Gruendl E, Dorobek B, Card no M, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001;143:1-8 https://doi.org/10.1046/j.1365-2133.2000.03581.x
  12. Van Leent EJ, Graeber M, Thurston M, Wagenaar A, Spuls PI, Bos JDl. Effective of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998;134:805-809 https://doi.org/10.1001/archderm.134.7.805
  13. European Study Group Graeber M, Hedgecock S. SDZ ASM 981 cream: an emerging new drug for the treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 1998; 11(Suppl 2):S198
  14. Van Leent EJM, Ebelin ME, Burtin P. Low systemic concentrations of SDZ ASM 981 after topical treatment of extensive atopic dermatitis lesions. J Eur Acad Dermatol Venereol 1998;11(Suppl 2):S133-S134
  15. Pariser D, Paller A, Langley R, Paul C. Efficacy and local tolerability of pimecrolimus cream 1% in the treatment of atopic dermatitis in the face/neck region of pediatric subjects. J Invest Dermatol 2002;119:348
  16. Boguniewicz M, Eichenfield L, Honig P, Langely R, Lucky A, Paller A, et al. Pimecrolimus (SDZ ASM 981) cream 1% is safe in the long-term management of atopic derma titis. J Eur Acad Dermatol Venereol 2001;15(Suppl 2):S110
  17. Kapp A, Bingham A, De Moor A, De Prost Y, Papp K, Potter PC, et al. Pimecrolimus (Elidel, SDZ ASM 981) cream 1%: a new approach of long-term management of atopic dermatitis in infants. J Eur Acad Dermatol Venereol 2001;15(Suppl 2):S111
  18. Leung DY, Soter NA. Cellular and immunologic mechanism in atopic dermatitis. J Am Acad Dermatol 2001;44(Suppl 1):S1-S12
  19. Eigenmann PA, Sicherer SH, Borkowski TA, Cohen BA, Sampson HA. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 1998;101: E8
  20. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003;361: 151-160 https://doi.org/10.1016/S0140-6736(03)12193-9
  21. Krutmann J, Diepgen TL, Luger TA, Grabbe S, Meffert H, Sonnichsen N, et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol 1998;38:589-593 https://doi.org/10.1016/S0190-9622(98)70123-9
  22. Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001;357:2012-2016 https://doi.org/10.1016/S0140-6736(00)05114-X
  23. Hanifin JM, Schneider LC, Leung DY, Ellis CN, Jaffe HS, Izu AE, et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993;28:189-197 https://doi.org/10.1016/0190-9622(93)70026-P
  24. Jolles S. A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. Clin Exp Dermatol 2002;27:3-7 https://doi.org/10.1046/j.0307-6938.2001.00955.x
  25. Sowden JM, Berth-Jones J, Ross JS, Motley RJ, Marks R, Finlay AY, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991;338:137-140 https://doi.org/10.1016/0140-6736(91)90134-B
  26. Granlund H, Erkko P, Sinisalo M, Reitamo Sl. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therpy. Br J Dermatol 1995;132:106-112 https://doi.org/10.1111/j.1365-2133.1995.tb08633.x
  27. Hill CJ, Rosenberg A Jr. Adverse effects from topical steroids. Cutis 1978;21:624-628
  28. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C. Cushing's syndrome after topical application of corticosteroids. Am J Dis Child 1982;136:274-275
  29. McLean CJ, Lobo RF, Brazier DJ. Cataracts glaucoma, and femoral avascular necrosis caused by topical corticosteroid ointment. Lancet 1995;345:330
  30. Bode HH. Dwarfism following long-term topical corticosteroid therapy. JAMA 1980;244:813-814 https://doi.org/10.1001/jama.244.8.813
  31. Queille C, Pommarede R, Saurat JH. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of chilidhood. Pediatr Dermatol 1984;1:246-253 https://doi.org/10.1111/j.1525-1470.1984.tb01124.x
  32. Nakagawa H, Etoh T, Ishibashi Y, Higaki Y, Kawashima M, Torii H, et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994;344:883
  33. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997;337:816-821 https://doi.org/10.1056/NEJM199709183371203
  34. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001;44(Suppl 1):S58-S64
  35. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000;136:999-1006 https://doi.org/10.1001/archderm.136.8.999
  36. Paller AS. Use of nonsteroidal topical immunomodulators for the treatment of atopic ezema in the pediatric population. J Pediatr 2001;138:163-168 https://doi.org/10.1067/mpd.2001.112245
  37. Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002;109:539-546
  38. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002;109:547-555 https://doi.org/10.1067/mai.2002.121832